Inebilizumab
Sign in to saveInebilizumab, sold under the brand name Uplizna, is a medication used for the treatment of neuromyelitis optica spectrum disorder, immunoglobulin G4-related disease, and generalized myasthenia gravis. Inebilizumab is a humanized monoclonal antibody that binds to and depletes CD19+ B cells including plasmablasts and plasma cells (a CD19-directed cytolytic antibody).
In the Vinony graph
Within Vinony's link graph, Inebilizumab is referenced by 255 other articles, and connects out to monoclonal antibody, humanized antibody and lumiliximab.
It sits within the topics Antineoplastic drugs, Chemicals that do not have a ChemSpider ID assigned and Drugs developed by Amgen.
Its subject is documented across 10 Wikipedia language editions.
Wikidata facts
- Subclass of
- chemical compound
Show 1 more fact
- subject has role
- monoclonal antibody
via Wikidata · CC0
~5 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects
- History
- Society and culture
- Legal status
- Names
- References
- Further reading
- External links
Inebilizumab, sold under the brand name Uplizna, is a medication used for the treatment of neuromyelitis optica spectrum disorder, immunoglobulin G4-related disease, and generalized myasthenia gravis. Inebilizumab is a humanized monoclonal antibody that binds to and depletes CD19+ B cells including plasmablasts and plasma cells (a CD19-directed cytolytic antibody).
The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain.
Excerpted from Wikipedia’s “Inebilizumab” article, available under the CC BY-SA 4.0 licence.